<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Head and neck squamous cell carcinogenesis: Molecular and genetic alterations</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Head and neck squamous cell carcinogenesis: Molecular and genetic alterations</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Head and neck squamous cell carcinogenesis: Molecular and genetic alterations</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lara Dunn, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles M Rudin, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce E Brockstein, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Squamous cell carcinogenesis in the mucosa of the head and neck involves the progressive accumulation of a large series of genetic abnormalities in genes regulating cell cycle progression, mitogenic and differentiative signaling pathways, angiogenesis, and cell death. This mutagenic progression, called multistep carcinogenesis, parallels the genetic model of colorectal carcinogenesis [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/z/d/html/2485.html" rel="external">"Molecular genetics of colorectal cancer"</a>.)</p><p>Evidence for a mutational progression in tumorigenesis of head and neck squamous cell carcinoma (HNSCC) first derived from cytogenetic studies that demonstrated nonrandom clonal losses, duplications, and rearrangements of chromosome segments in head and neck tumors [<a href="#rid3">3-5</a>]. Within many of these regions of recurring chromosomal abnormality, candidate oncogenes or tumor suppressors have since been identified, some of which appear to play critical roles in carcinogenic transformation. Subsequent detailed progression models for carcinogenesis of the head and neck have been based on mutational models and differential gene expression [<a href="#rid6">6,7</a>]. Using contemporary sequencing technologies, we have developed a better understanding of the mutational landscape in HNSCC [<a href="#rid8">8-10</a>]. </p><p>Identifying critical genetic events that lead to the development of head and neck cancer has further clarified the molecular basis for specific risk factors, such as tobacco and alcohol, as well as human papillomavirus (HPV) infection. This information has become critical for risk stratification and may result in modifications to standard treatment paradigms. (See  <a class="medical medical_review" href="/z/d/html/3390.html" rel="external">"Epidemiology and risk factors for head and neck cancer"</a> and  <a class="medical medical_review" href="/z/d/html/3378.html" rel="external">"Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer"</a>.)</p><p>In addition, these studies have unveiled a new series of targets for chemotherapeutic and chemopreventive intervention, which ultimately may result in more rational and successful therapies for this disease. (See  <a class="medical medical_review" href="/z/d/html/3391.html" rel="external">"Chemoprevention and screening in oral dysplasia and squamous cell head and neck cancer"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">FIELD CANCERIZATION</span><span class="headingEndMark"> — </span>The term field cancerization was first used to describe observations from microscopic examination of 738 lip, oral cavity, and pharyngeal carcinomas [<a href="#rid11">11</a>]. The grossly normal epithelium adjacent to the cancer in this study frequently contained dysplasia, carcinoma in situ, or invasive carcinoma, as though the entire mucosal field had been damaged and preconditioned by a carcinogen.</p><p>The molecular basis for field cancerization has been studied by evaluating matched dysplastic and malignant lesions within the oral cavity for genetic alterations [<a href="#rid12">12</a>]. Two important observations were made:</p><p class="bulletIndent1"><span class="glyph">●</span>Four of the 15 dysplastic lesions harbored the same genetic abnormalities detected in the tumor. The finding of identical genetic lesions in dysplastic lesions and invasive cancer in the same patient provided further evidence that dysplasias were precursor lesions and that multiple lesions can arise due to the lateral migration of genetically altered cells through the oral mucosa (a phenomenon termed clonal cancerization [<a href="#rid13">13</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eight of the 15 dysplastic lesions showed genetic alterations not found in the matched cancer. This provided evidence that multifocal disease can arise from the development of several genetically altered clones from different initiating events.</p><p></p><p>The importance of dysplastic lesions as precursors to malignancy was illustrated in a retrospective study of 97 cases of epithelial dysplasia in the head and neck region [<a href="#rid14">14</a>]. Fifty patients developed a squamous cell carcinoma in the same area as the dysplastic lesion at a mean follow-up of 30 months.</p><p>Support for field cancerization is also provided by the development of second or multiple primaries in patients with head and neck squamous cell carcinoma. Cancer at one site in the head and neck is a strong predictor for the development of a second primary tumor elsewhere. Second tumors can either occur at or close to the same time as the primary lesion (synchronous), or at least six months later (metachronous). As with dysplasia, the second tumors may be clonally similar to or distinct from the primary tumor. (See  <a class="medical medical_review" href="/z/d/html/3393.html" rel="external">"Overview of the diagnosis and staging of head and neck cancer", section on 'Incidence of second and multiple primaries'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">GENOMIC ALTERATIONS AND MULTISTEP CARCINOGENESIS</span><span class="headingEndMark"> — </span>Multistep carcinogenesis describes the series of events (initiation, promotion, progression) that leads to the development of invasive carcinoma. Although the specific sequence of genetic events has not been defined, numerous molecular mutations and genetic alterations have been found in both carcinomas and premalignant tissue.</p><p>A large number of studies examining chromosomal abnormalities in head and neck squamous cell carcinoma (HNSCC) serve as the foundation for current models of squamous cell carcinogenesis and indicate the complexity of the transformation process. Cytogenetic analysis and more detailed loss of heterozygosity studies based on microsatellite analysis have demonstrated that particular chromosomal abnormalities are consistently observed in HNSCC. Among many others, regions found to be commonly lost include 9p21 (the site of the p16 <em>CDKN2A</em> and p14 <em>ARF</em> tumor suppressor genes), 9p34 (<em>NOTCH1</em> tumor suppressor or oncogene) [<a href="#rid8">8</a>], 17p13 (site of the p53 tumor suppressor gene and perhaps another tumor suppressor that remains to be identified), 11p15 (<em>HRAS</em> oncogene) [<a href="#rid15">15</a>], 3q26 (<em>PIK3CA</em> oncogene) [<a href="#rid8">8</a>], 10q23 (<em>PTEN</em> tumor suppressor gene) [<a href="#rid16">16</a>], 3p (the site of potential tumor suppressor genes, including <em>FHIT</em> and <em>RASSF1A</em>), 13q21 (unknown tumor suppressor near the retinoblastoma locus) [<a href="#rid6">6,17,18</a>], 18q21 (the site of the <em>DCC</em> gene) [<a href="#rid19">19</a>], and 5p (site of the <em>TERT</em> gene promoter) [<a href="#rid20">20</a>].</p><p>One study performed microsatellite analysis on a series of hyperplastic lesions, dysplastic lesions, carcinomas in situ, and invasive squamous cell carcinomas, examining these and other chromosomal loci [<a href="#rid6">6</a>]. The findings generated the first model of sequential genetic progression in head and neck squamous cell carcinogenesis, as illustrated in the figure  (<a class="graphic graphic_figure graphicRef79860" href="/z/d/graphic/79860.html" rel="external">figure 1</a>) [<a href="#rid21">21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Loss of 9p, leading to inactivation of the p16 tumor suppressor gene, was a very early event, occurring even in transition from normal to hyperplastic mucosa. Deletion involving the 9p21 locus is found in 70 percent of all HNSCC [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>This was frequently followed by loss of 3p and 17p in transition to dysplasia [<a href="#rid21">21</a>]. Among other putative tumor suppressors, 17p includes the p53 gene. The transition from dysplasia to carcinoma in situ was frequently associated with specific additional losses (11q, 13q, 14q) and still others (6p, 8, 4q) in the transition to invasive squamous cell carcinoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Despite early loss of 17p in this model, sequencing of p53 alleles indicated that loss of p53 function may occur significantly later in the course of malignant transformation.</p><p></p><p>These data were confirmed and extended by using comparative genomic hybridization, a technique that permits concurrent analysis of genetic gain and loss throughout the genome. When well-differentiated and poorly differentiated HNSCC were evaluated by this technique, there was evidence of genetic progression from well to poorly differentiated cancer [<a href="#rid23">23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Well-differentiated tumors consistently demonstrated underrepresentation (loss) of chromosomes 3p, 5q, and 9p, together with overrepresentation (gain) of 3q.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poorly differentiated tumors typically shared these aberrations but had other abnormalities, such as evidence of deletion of 4q, 6q, 8p, 11q, 13q, 18q, and 21q and overrepresentation of 1p34-pter, 11q13, 19, and 22q.</p><p></p><p>The inactivation of tumor suppressor genes by epigenetic mechanisms has now been reported in HNSCC. Promoter hypermethylation as a mechanism of tumor suppressor gene inactivation has been noted with the <em>DCC</em> gene, the retinoic acid receptor (RAR)-beta2, P16, and the O6-methylguanine-DNA methyltransferase (<em>MGMT</em>) gene [<a href="#rid19">19,24</a>].</p><p>These arrays of genomic alterations underscore the complexity of carcinogenic transformation and are consistent with studies in other tumor models, suggesting that many genetic alterations, perhaps involving 10 or more genes, are necessary for fully malignant growth [<a href="#rid25">25</a>]. There is great interest in defining the extent to which individual molecular markers dictate prognosis in HNSCC [<a href="#rid26">26,27</a>].</p><p>The Cancer Genome Atlas (TCGA) profiled 279 HNSCC specimens and evaluated the DNA/RNA structural alterations, somatic mutations, genomic alterations by site, stage, human papillomavirus (HPV) status, molecular subtypes, and putative biomarkers. This study is the most comprehensive integrative genomic analysis of HNSCC. With HPV associated tumors, the loss of <em>TRAF3</em>, activating mutations in <em>PIK3CA</em>, and amplification of <em>E2F1</em> were more common. With non-HPV associated tumors, co-amplification of 11q13 and 11q22, focal deletions in nuclear the set domain gene/tumor suppressor genes, and focal amplifications in receptor tyrosine kinases were more common. The figure highlights the frequency of genetic alterations for HPV associated and non-HPV associated tumors  (<a class="graphic graphic_figure graphicRef105412" href="/z/d/graphic/105412.html" rel="external">figure 2</a>) [<a href="#rid28">28</a>]. </p><p>Next-generation sequencing of 252 formalin-fixed, paraffin-embedded HNSCC tumors found the most common alterations to be <em>PIK3CA</em> in HPV associated tumors and <em>TP53 </em>and <em>CDKNN2A/B</em> in the non-HPV associated tumors. In HPV associated tumors, several alterations along the PI3K pathway were present, including alterations of <em>PTEN</em>, <em>AKT1</em>, <em>RICTOR</em>, <em>mTOR</em>, <em>AKT2</em>, and <em>PIK3R1</em>, in addition to <em>PIK3CA</em> [<a href="#rid16">16</a>].</p><p>Next-generation sequencing in 53 patients with advanced HNSCC showed that recurrent and/or metastatic non-HPV associated and HPV associated tumors had similar mutation counts and copy number-altered fraction of genome [<a href="#rid29">29</a>], unlike other studies that suggested higher mutational burden in non-HPV associated primary tumors. As compared with HPV associated tumors, non-HPV associated tumors had more frequent alterations in <em>TP53</em>, <em>TERT</em> promoter, and <em>CDKN2A</em>. Additionally, the mutational profile of advanced non-HPV associated tumors closely resembled non-HPV associated primary tumors sequenced by TCGA, whereas the mutational profile of HPV associated tumors demonstrated profiles that were intermediate between HPV associated and non-HPV associated tumors sequenced by TCGA. Advanced (ie, recurrent and metastatic) HPV associated tumors were consistently found to have higher frequencies of <em>TP53</em> mutations and lower frequencies of <em>PIK3CA</em> mutations compared with primary HPV associated tumors [<a href="#rid20">20,29,30</a>]. These findings provide insight into HNSCC genomic alterations based on HPV status and disease setting.</p><p class="headingAnchor" id="H4"><span class="h1">DISRUPTION OF MITOGENIC SIGNALING PATHWAYS</span><span class="headingEndMark"> — </span>Mitogenic signaling pathways initiated through cell surface receptors are disrupted in most cancers, including head and neck squamous cell carcinoma (HNSCC). Dysregulated factors have included both downstream signaling molecules, such as Ras [<a href="#rid31">31</a>], and a number of transmembrane receptors and their ligands. Particular attention has been focused on the epidermal growth factor receptor (EGFR) as a factor in carcinogenesis and as a therapeutic target, as well as the closely related human epidermal growth factor receptor 2 (HER2 [c-erbB-2]) receptor [<a href="#rid32">32-39</a>]. Both of these receptors have cytoplasmic domains with tyrosine kinase activity and activate a number of intracellular second messenger pathways.</p><p class="headingAnchor" id="H5"><span class="h2">EGFR and transforming growth factor-alpha</span><span class="headingEndMark"> — </span>Both EGFR and its principal ligand, transforming growth factor (TGF)-alpha, are upregulated in HNSCC, constituting an autocrine activation loop [<a href="#rid36">36</a>]. TGF-alpha overexpression is frequently induced relatively early in carcinogenesis, being elevated in mild dysplasia, with no further increases in advanced dysplasias or carcinoma. In contrast, EGFR expression usually increases progressively with increasing degree of dysplasia and is markedly elevated in many fully transformed HNSCCs [<a href="#rid32">32,36</a>]. EGFR appears to be upregulated to some extent in more than 90 percent of HNSCCs [<a href="#rid33">33,34</a>]. High EGFR levels in HNSCC, as assessed by either protein expression or gene copy number, are associated with shorter overall and progression-free survival [<a href="#rid40">40</a>]. In addition, clinical studies have confirmed the importance of EGFR as a therapeutic target for HNSCC [<a href="#rid41">41</a>] with <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> as the only US Food and Drug Administration (FDA)-approved targeted therapy in HNSCC. (See  <a class="medical medical_review" href="/z/d/html/3364.html" rel="external">"Treatment of metastatic and recurrent head and neck cancer"</a>.)</p><p class="headingAnchor" id="H357541690"><span class="h2">Ras-mediated pathway: Raf/MEK/ERK and PI3K</span><span class="headingEndMark"> — </span>The Ras family includes three genes: <em>HRAS</em>, <em>KRAS</em>, and <em>NRAS</em>. In HNSCC, these tumors exhibit exclusively <em>HRAS</em> mutation, which is seen in 35 percent of oral cancers in India [<a href="#rid42">42,43</a>]. In the United States, this is not as common and is seen in only 4 to 5 percent of HNSCC tumors [<a href="#rid9">9,10</a>]. <em>RAS</em> mutations activate the Raf/MEK/ERK pathway and the PI3K pathway, both of which are involved with cell proliferation, differentiation, and cell survival. In HNSCC, overactivation of the PI3K pathway occurs by<em> PI3KCA</em> mutation, which is seen in 6 to 8 percent of cases, or <em>PTEN</em> loss, which is seen in 10 percent of tumors [<a href="#rid44">44,45</a>]. <em>RAS</em> mutations and <em>PIK3CA</em> amplifications, not <em>PIK3CA</em> mutations, have been associated with poorer progression-free survival [<a href="#rid30">30</a>].</p><p>Several clinical trials targeting the PI3K pathway, as a single agent or in combination, are ongoing. Other trials are evaluating the use of a farnesyltransferase inhibitor in <em>HRAS</em> mutant head and neck cancer. (See  <a class="medical medical_review" href="/z/d/html/3364.html" rel="external">"Treatment of metastatic and recurrent head and neck cancer", section on 'Investigational approaches'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">HER2 gene product</span><span class="headingEndMark"> — </span>The HER2 gene product (also known as c-erbB-2) has extensive structural homology to EGFR and is overexpressed in many solid tumors, including breast, lung, ovarian, and gastric cancers. In all of these sites, HER2 overexpression has been identified as a negative prognostic factor. Upregulation of HER2 occurs in approximately 50 percent of all HNSCCs [<a href="#rid37">37,38</a>]. In addition to its role in mitogenesis, HER2 signaling is thought to increase metastatic potential through induction of a diverse collection of factors involved in altering cell-cell adhesion and invasiveness. Like EGFR, HER2 expression has been correlated with decreased overall survival in HNSCC in many [<a href="#rid39">39,46,47</a>], but not all, studies [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Src kinase</span><span class="headingEndMark"> — </span>Since the discovery of EGFR and targeted agents that inhibit the EGFR, research has been focused on mechanisms of resistance to EGFR inhibitors. One emerging target is the nonreceptor kinase src, a downstream component of the EGFR signaling complex [<a href="#rid49">49</a>]. Activated src phosphorylates the intracellular domain of EGFR and mediates the activation of the STAT3 pathway by EGFR [<a href="#rid50">50</a>]. Src kinase is also integral to GRP-induced EGFR activation and downstream signaling via the mitogen-activated protein kinase (MAPK) pathway. In one study, targeted inhibition of src family tyrosine kinase activity resulted in decreased GRP-induced EGFR activation and MAPK phosphorylation [<a href="#rid51">51</a>].</p><p>Constitutive activation of src may mediate resistance to EGFR inhibitors, and resistance might be overcome clinically by combined inhibition of both targets, src and EGFR. Among small-molecule tyrosine kinase inhibitors in clinical development, <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">dasatinib</a> and saracatinib inhibit the src family kinase activity in a highly selective manner [<a href="#rid52">52,53</a>]. Phase I/II trials targeting the src pathway and EGFR pathways in patients with HNSCC are ongoing.</p><p class="headingAnchor" id="H10"><span class="h1">DISRUPTION OF CELL CYCLE CONTROL</span><span class="headingEndMark"> — </span>Many of the factors that are known to play a critical role in regulating cell cycle entry (particularly cyclin D1, the p16 cyclin-dependent kinase [CDK] inhibitor, p53, and c-myc) are dysregulated in head and neck squamous cell carcinoma (HNSCC).</p><p class="headingAnchor" id="H11"><span class="h2">Overexpression of cyclin D1</span><span class="headingEndMark"> — </span>Overexpression of cyclin D1, encoded by <em>CCND1</em>, has been observed in HNSCC. Cyclin D1 pairs with CDK4 and CDK6 to promote cell cycle progression in the G1-S transition, which is critical to commitment to replication and division [<a href="#rid54">54</a>]. CCND1 polymorphism, thought to alter cyclin D1 expression, has been associated with HNSCC risk, tumor grade, tumor recurrence, and survival [<a href="#rid55">55-59</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Inactivation of the p16/p14 ARF locus</span><span class="headingEndMark"> — </span>p16 (<em>CDKN2</em>/<em>MTS1</em>) and p14 <em>ARF</em> are overlapping genes in the same locus, encoded by distinct open reading frames and distinct mRNA splice forms. Inactivation of this locus is the most common genetic alteration that has been described in HNSCC [<a href="#rid60">60</a>]. The gene product p16 is a potent inhibitor of both CDK4 and CDK6. Thus, inactivation of p16, as with overexpression of cyclin D1, increases CDK4/6 activity and promotes cell proliferation. On the other hand, re-expression of p16 in HNSCC cells results in significant antitumor effects, both in tissue culture and in animal models [<a href="#rid61">61,62</a>]. p14 <em>ARF</em> blocks association of p53 with its inhibitor MDM2. Thus, loss of p14 <em>ARF</em> leads to indirect inhibition of p53 function.</p><p class="headingAnchor" id="H13"><span class="h2">Inactivation of p53 tumor suppressor gene</span><span class="headingEndMark"> — </span>p53 is a critical antineoplastic factor, suppressing aberrant proliferation, both by inhibition of cell cycle progression and by induction of apoptotic cell death. The regulation of cell cycle by p53 is mediated primarily at the G1-S transition, both through transcriptional induction of cell cycle inhibitors, such as p21, and through transcription-independent mechanisms that are poorly understood.</p><p>The p53 gene is inactivated in at least one-half of HNSCCs [<a href="#rid63">63-70</a>], although some reports suggest that the mutation rate is higher, approaching 80 percent [<a href="#rid71">71</a>]. The timing of p53 inactivation in HNSCC tumorigenesis is controversial, with some reports demonstrating aberrant expression in early dysplasia and the majority suggesting mutation only late in tumor evolution [<a href="#rid6">6,63-65</a>]. The mechanism underlying loss of p53 expression depends on the risk factor for the development of HNSCC [<a href="#rid72">72,73</a>]. Loss of p53 expression through mutations or loss of heterozygosity is associated with a history of alcohol and tobacco use. As an example, in one study of 129 patients with primary HNSCC, p53 mutations were found in tumor samples in 58 percent of those who both smoked and used alcohol, in 33 percent who smoked but abstained from alcohol, and in 17 percent who neither smoked nor drank alcohol [<a href="#rid72">72</a>].</p><p>In contrast, there is an inverse relationship between the presence of p53 mutations and human papillomavirus (HPV) infection. In the setting of HPV infection, p53 is inactivated by binding to the E6 viral protein. (See <a class="local">'Human papillomavirus'</a> below.)</p><p class="headingAnchor" id="H14"><span class="h3">Prognostic impact</span><span class="headingEndMark"> — </span>Mutations in the p53 gene may also influence prognosis and response to treatment in both localized and locoregionally advanced HNSCC [<a href="#rid70">70,74-78</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 105 patients with locoregionally advanced head and neck cancer, the presence of a p53 mutation was associated with a statistically significant 70 percent less chance of responding to neoadjuvant chemotherapy as compared with wild-type p53 [<a href="#rid77">77</a>]. (See  <a class="medical medical_review" href="/z/d/html/3392.html" rel="external">"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The correlation between p53 mutations and outcome after surgical treatment was addressed in a retrospective analysis of 420 patients who underwent curative intent surgery for head and neck cancer on a prospective multicenter trial [<a href="#rid70">70</a>]. The mutations were classified as disruptive or nondisruptive based on the degree of predicted disturbance of the p53 protein structure. Patients whose tumors harbored p53 mutations (53 percent of all patients) had significantly reduced overall survival after surgical treatment compared with those with wild-type p53 (hazard ratio [HR] for death 1.4) [<a href="#rid70">70</a>]. The association was strongest for disruptive mutations (HR for death 1.7).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The association between p53 mutations and response to larynx-preserving surgery was studied in a series of 71 patients with locoregionally advanced head and neck cancer who were treated on larynx-preserving protocols [<a href="#rid78">78</a>]. Tumors were assayed for immunohistochemical expression of p53, its upstream regulator <em>MDM2</em>, and its downstream transcriptional target p21/<em>WAF1</em>. In a multivariate analysis, no molecular marker significantly predicted the response to induction chemotherapy. However, compared with those with wild-type p53, patients with p53 positive tumors had significantly worse five-year survival (29 versus 51 percent) with larynx preservation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although p53 mutations are infrequent in HPV associated disease, complete inactivation of p53 in HPV associated HNSCC cell lines was associated with resistance to radiation therapy and aggressive tumor behavior [<a href="#rid79">79</a>].</p><p></p><p class="headingAnchor" id="H357541823"><span class="h2">NOTCH-1 gene</span><span class="headingEndMark"> — </span>Mutations with the <em>NOTCH-1</em> gene were noted in 15 and 14 percent of HNSCC in two studies with next-generation sequencing [<a href="#rid9">9,10</a>]. <em>NOTCH-1</em> is believed to play a role in regulating normal cell differentiation and has both oncogenic and tumor suppressor activity [<a href="#rid9">9,42</a>]. In HNSCC, <em>NOTCH-1</em> appears to act as a tumor suppressor gene, and the majority of the mutations are likely loss of function mutations that affect the epidermal growth factor (EGF)-like ligand binding domain or the NOTCH intracellular domain (NICD). Therapeutically targeting <em>NOTCH-1</em> in HNSCC is an evolving field.</p><p class="headingAnchor" id="H15"><span class="h2">c-myc oncogene</span><span class="headingEndMark"> — </span>The c-myc oncogene is a potent proliferative factor that, when overexpressed, can promote G1-S transition by mechanisms that have not been defined. Amplification of the c-myc locus occurs frequently in HNSCC, and c-myc upregulation has been correlated with decreased overall survival [<a href="#rid80">80,81</a>].</p><p class="headingAnchor" id="H3578527293"><span class="h2">TERT gene promoter</span><span class="headingEndMark"> — </span>The telomerase reverse transcriptase (<em>TERT</em>) gene encodes the reverse transcriptase subunit of telomerase that maintains the telomere length through synthesis of telomere units at the ends of chromosomes. In one study, approximately 75 percent of oral cavity squamous cell carcinomas exhibited <em>TERT</em> promoter mutations C228T and C250T [<a href="#rid20">20</a>]. Another report detected <em>TERT</em> mutations in 34 percent of HNSCC tumors, predominantly among oral cavity cancers [<a href="#rid82">82</a>]. <em>TERT</em> mutations were also more prevalent in advanced non-HPV associated tumors than non-HPV associated primary tumors [<a href="#rid29">29</a>]. The prognosis of a <em>TERT</em> mutation has been associated with a significant decrease in disease-free survival and overall survival [<a href="#rid82">82</a>]. </p><p class="headingAnchor" id="H16"><span class="h2">Human papillomavirus</span><span class="headingEndMark"> — </span>Oncogenic viruses are another factor that can affect cell cycle regulation. In situ hybridization and polymerase chain reaction (PCR)-based detection have demonstrated that as many as one-third of all HNSCCs and 60 percent of oropharyngeal cancers contain HPV, with the majority of these containing high-risk oncogenic HPV types 16, and fewer contain HPV types 18 or 33. The molecular profile of HPV associated HNSCCs is distinct from those that are non-HPV associated, with almost all HPV associated tumors expressing wild-type tumor suppressor genes p53 and p16. This would suggest different mechanisms of oncogenesis for HPV associated as compared with non-HPV associated tumors, and that HPV infection is an early event in head and neck squamous cell carcinogenesis. (See  <a class="medical medical_review" href="/z/d/html/3378.html" rel="external">"Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer", section on 'Biology of HPV'</a>.)</p><p>HPV associated head and neck cancers respond more favorably to regimens using chemotherapy and radiation therapy than do those with non-HPV associated tumors. These data are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3390.html" rel="external">"Epidemiology and risk factors for head and neck cancer", section on 'Human papillomavirus'</a> and  <a class="medical medical_review" href="/z/d/html/115014.html" rel="external">"Treatment of human papillomavirus associated oropharyngeal cancer"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">DISRUPTION OF CELL-CELL CONTACT AND DIFFERENTIATION PATHWAYS</span><span class="headingEndMark"> — </span>Cellular differentiation is, in part, regulated by a transcriptional program determined by expression of nuclear retinoic acid receptors. Retinoic acid receptors are bipartite transcription factors composed of RAR and RXR components, and multiple members of both the RAR and RXR families can associate to differentially regulate arrays of downstream targets.</p><p>Histologic progression in premalignant dysplastic lesions of the head and neck has been associated with loss of nuclear RAR-beta expression [<a href="#rid83">83</a>]. Treatment of such lesions with 13-cis retinoic acid can result in recovery of normal nuclear RAR-beta expression and may lead to re-establishment of a normal differentiation program in the affected mucosa [<a href="#rid84">84,85</a>]. These observations have spawned an enormous interest in retinoid research, particularly among investigators interested in chemoprevention.</p><p class="headingAnchor" id="H20"><span class="h2">E-cadherin</span><span class="headingEndMark"> — </span>Epithelial tissue structure is dependent on a complex network of cell-cell adhesions, and loss of cell-cell contact has been associated with tumor invasiveness and metastatic potential in many cancers. One of the critical factors in these networks that has been most clearly linked to cancer progression is E-cadherin (CDH1). Invasion in an E-cadherin negative tumor cell line can be suppressed by transfection with E-cadherin, and invasiveness can be restored by anti-E-cadherin antibodies [<a href="#rid86">86</a>]. Loss of E-cadherin expression in HNSCC has been found to correlate with both the extent of dedifferentiation of the tumor and, more importantly, with the probability of lymph node metastasis [<a href="#rid87">87-89</a>]. The mechanism of E-cadherin inactivation in HNSCC is not known.</p><p class="headingAnchor" id="H21"><span class="h2">Matrix metalloproteinases</span><span class="headingEndMark"> — </span>The matrix metalloproteinases (MMPs), a family of secreted enzymes that degrade extracellular matrix proteins, have been implicated in the normal processes of tissue regeneration and remodeling. Expression of certain members of the MMP family, including MMP-2, MMP-9, and MMP-13, has been associated with increased local invasion, high metastatic potential, and poor clinical outcome in HNSCC [<a href="#rid90">90-92</a>]. In addition, the expression of a natural inhibitor of MMPs, TIMP-1, also appears to have prognostic significance in patients with HNSCC [<a href="#rid93">93,94</a>]. Tumor expression of MMPs may be an important determinant of tumor growth, spread, and clinical outcome.</p><p>A prospective study from Johns Hopkins collected tumor samples from 124 patients with HNSCC and evaluated for promoter hypermethylation for <em>TIMP-3</em> and DAPK using a quantitative methylation-specific polymerase chain reaction (qMSP) [<a href="#rid95">95</a>]. <em>TIMP-3</em> is a known tumor suppressor gene on chromosome 12q 12.3 and is part of a family of genes that inhibit MMPs. <em>TIMP-3</em> regulates processes including invasion, migration, differentiation, and proliferation. DAPK is a serine-threonine kinase found to be an integral part of the interferon-induced apoptotic pathway. <em>TIMP-3</em> was hypermethylated in 71.8 percent of the tumor samples, and DAPK was hypermethylated in 74.2 percent, both significantly higher than in control specimens. There was a strong correlation for hypermethylation between the two genes. The roles of these genes in HNSCC tumorigenesis are being actively studied.</p><p>MMPs represent a potential therapeutic target. Although initial clinical trials with small-molecule MMP inhibitors in advanced solid tumors have been disappointing, evaluation in patients with very early stage disease (in which these agents might be predicted to be of greatest potential efficacy) has not been undertaken [<a href="#rid96">96</a>].</p><p class="headingAnchor" id="H22"><span class="h1">DISRUPTION OF CELL DEATH PATHWAYS</span><span class="headingEndMark"> — </span>Inhibition of programmed cell death (apoptosis) pathways by either cellular or viral mechanisms is a characteristic feature of many human cancers [<a href="#rid97">97</a>]. Overexpression of transforming oncogenes, in the absence of apoptotic inhibition, efficiently triggers programmed cell death in many contexts, including cultured epithelial cells [<a href="#rid98">98,99</a>]. These observations suggest that apoptotic dysregulation may be a critical event in the process of carcinogenesis.</p><p>Among the many other factors known to regulate apoptotic pathways are the B cell leukemia/lymphoma 2 (Bcl-2) family members. This family consists of both proapoptotic and antiapoptotic members that form heterodimers that determine apoptotic threshold [<a href="#rid100">100</a>]. Approximately 70 percent of HNSCCs demonstrate upregulated expression of one of two antiapoptotic genes in this family, <em>Bcl-xL</em> and <em>Bcl-2</em> [<a href="#rid101">101</a>].</p><p>Multiple studies have found an association between <em>Bcl-2</em> overexpression and better clinical outcome, including response to chemotherapy, local control, time to progression, and survival [<a href="#rid101">101-103</a>]. This finding is surprising since apoptotic inhibition by factors such as <em>Bcl-2</em> confers both chemotherapeutic and radiation resistance in cell lines [<a href="#rid15">15</a>] and might be expected to promote viability of micrometastases, resulting in a highly resistant and rapidly spreading cancer. Although a similar paradoxical finding has been noted in other solid tumors, the basis for this association has not been determined.</p><p class="headingAnchor" id="H13687059"><span class="h1">IMMUNE LANDSCAPE AND PD-1/PD-L1 PATHWAY IN HNSCC</span><span class="headingEndMark"> — </span>The human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCC) arises from deep crypts within the tonsillar and base of tongue lymphoid tissue, characterized by infiltration of lymphocytes in the stroma and tumor nests [<a href="#rid104">104</a>]. Despite this lymphocytic infiltration of tumor tissue, the HPV associated tumors are able to evade the immune system and proliferate. This may be related to dysregulation of antigen-induced activation and overexpression of co-inhibitory receptors/ligands on the tumor cell surface/lymphocytes, such as programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1), referred to as immune checkpoints. Most studies suggest a positive correlation between PD-L1 expression and HPV positivity [<a href="#rid105">105</a>]. Checkpoint inhibitors specifically targeting PD-1 and PDL1 have significant clinical activity in patients with metastatic HNSCC. (See  <a class="medical medical_review" href="/z/d/html/3364.html" rel="external">"Treatment of metastatic and recurrent head and neck cancer", section on 'PD-1 inhibitor immunotherapy'</a>.)</p><p>Overexpression of PD-L1 in tumor cells commonly results from induction of cytokines, such as interferon (IFN)-gamma secreted by the immune cells, as well as intrinsic mechanisms. The PI3K pathway has been implicated in PD-L1 expression in oral cavity cancer. IFN-gamma was shown to induce PD-L1 expression by upregulation of protein kinase D isoform 2, a downstream target of PI3K [<a href="#rid106">106,107</a>]. Furthermore, inactivation of PTEN has been observed to be associated with increased PD-L1 expression [<a href="#rid108">108</a>].</p><p>The prognostic value of PD-1/PD-L1 expression in HNSCC remains controversial. Some studies suggest that PD-L1 expression is associated with tumor size, clinical stage, regional and distant metastases, and worse overall survival [<a href="#rid109">109,110</a>]. Other studies suggest that higher PD-1/PD-L1 expression correlated with fewer local and distant recurrences, especially in those with HPV associated disease [<a href="#rid111">111</a>]. Yet other studies found that PD-L1 expression did not correlate with prognosis in HNSCC [<a href="#rid111">111</a>]. As an example, one meta-analysis did not detect a difference in survival between patients with PD-L1-positive and PD-L1-negative tumors [<a href="#rid112">112</a>]. </p><p>Alternately, PD-L1 expression on immune cells rather than tumor cells may carry predictive value. A combined positive score (CPS), which takes into account PD-L1 expression on lymphocytes, macrophages, and tumor cells, is used to guide therapy in HNSCC [<a href="#rid112">112,113</a>]. Further details on the use of CPS score and immunotherapy in advanced and metastatic head and neck cancer are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3364.html" rel="external">"Treatment of metastatic and recurrent head and neck cancer"</a>.)</p><p>Our understanding of the role of immune infiltration, activation, and immunoregulatory influence in HNSCC is evolving. Clinical trials are needed to determine whether information about the tumor immune microenvironment should inform therapy decisions. The following studies provide insight into the immune landscape of HNSCC.</p><p>An analysis of 280 HNSCC tumors previously profiled by The Cancer Genome Atlas (TCGA) found that HNSCC is one of the highly immune-infiltrated and immune-regulated cancer types [<a href="#rid114">114</a>]. Immune infiltration differed by tumor subsite, HPV status, and tobacco smoking:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor subsite</strong> – Tumors arising in the oropharynx had higher levels of T cell infiltration, with higher levels of immunoregulatory influence manifested by a lower CD8<sup>+</sup>/Treg ratio compared with oral cavity, hypopharynx, and larynx subsites. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human papillomavirus status</strong> – HPV associated tumors contained higher levels of infiltrating Tregs and CD8<sup>+</sup> T cells, and higher expression of the immuno-inhibitory receptor cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) compared with non-HPV associated HNSCC. PD-1 and PD-L1 expression was comparable in HPV associated and non-HPV associated tumors. Compared with other highly immune-infiltrated cancer types, the HPV associated and non-HPV associated HNSCC tumors had the highest levels of infiltration with CD56<sup>dim</sup> NK cells. CD56<sup>dim</sup> NK cells are inhibited by killer cell immunoglobulin-like receptors (KIR), and <em>KIR</em> gene expression was higher in HPV associated tumors. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tobacco smoking</strong> – HNSCC with a genetic smoking signature (high mutational loads) had low levels of immune infiltration and correlated with poor survival, offering a potential explanation for the known association between tobacco smoking and inferior prognosis in patients with HPV associated HNSCC [<a href="#rid115">115-117</a>]. </p><p></p><p>Another study of 522 HNSCC tumors from TCGA analyzed the immune pathway-related gene expression profile using RNA sequencing [<a href="#rid118">118</a>]. Significant enrichment of immune cells (T cell, B cell, macrophages), immune-related patterns of gene expression (T/NK and B/P metagenes), and interferon alpha gene signatures were identified in 40 percent of HNSCC tumors (termed "immune class tumors"). These "immune class tumors" had better overall survival than "non-immune class tumors." Immune class tumors could be subdivided based on the absence ("active immune class") or presence ("exhausted immune class") of activated stroma in the tumor microenvironment: </p><p class="bulletIndent1"><span class="glyph">●</span>The "active immune class" was characterized by B cell-related immune signatures, cytolytic activity, and proinflammatory M1 macrophages, suggesting that the humoral immune response could influence intratumoral immune response activation and exhaustion. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The "exhausted immune class" was characterized by antiinflammatory M2 macrophages, activated stroma, and other tumor-promoting signals, such as the WNT/transforming growth factor (TGF)-beta signaling pathway, suggesting that these could suppress host immune response. </p><p></p><p>The "active immune class" profile was associated with superior prognosis and was seen more commonly in tumors of the oropharynx, those with HPV infection identified by p16 immunohistochemistry/HPV in situ hybridization, and early pathologic T stage.</p><p>Further studies are needed to determine whether tumor immune class might be used to tailor treatment strategies. One hypothesis is that the "active immune class" may be more likely to respond to single-agent checkpoint inhibitors, whereas the "exhausted immune class" may need a combination of treatments (eg, a checkpoint inhibitor plus a TGF-beta inhibitor), and the "non-immune class" may require a combination that would attract T cell infiltration into the tumor microenvironment (eg, a combination of anti-CTLA-4 and anti-PD-1/PD-L1 therapy) [<a href="#rid118">118</a>].</p><p class="headingAnchor" id="H3754689852"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/128559.html" rel="external">"Society guideline links: Head and neck cancer"</a>.)</p><p class="headingAnchor" id="H821162216"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/83256.html" rel="external">"Patient education: Throat cancer (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/83257.html" rel="external">"Patient education: Tongue cancer (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/83251.html" rel="external">"Patient education: Laryngeal cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Our molecular understanding is rapidly progressing regarding the development of head and neck squamous cell carcinoma (HNSCC) as well as the influence of the immune landscape in this disease. Data reiterate the complexity of carcinogenic transformation noted in other solid tumor models.</p><p></p><p class="bulletIndent1">Molecular analysis of the p53 gene mutations and increased mutational load in smokers versus nonsmokers solidified the causal relationship between carcinogens in tobacco and HNSCC. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The genetic alterations associated with progressive stages of carcinogenic transformation and a better understanding of the immune infiltration, activation, and regulation in development of HNSCC may be relevant to the success of chemopreventive strategies in addition to histologic analysis. (See <a class="local">'Genomic alterations and multistep carcinogenesis'</a> above and  <a class="medical medical_review" href="/z/d/html/3391.html" rel="external">"Chemoprevention and screening in oral dysplasia and squamous cell head and neck cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many of the molecular defects identified in the above studies have yielded new targets that may result in novel therapeutic approaches in HNSCC and other cancers. Strategies have been developed to target cells with aberrant expression of epidermal growth factor (EGF), human epidermal growth factor 2 (HER2), HRAS, B cell leukemia/lymphoma 2 (Bcl-2), p53, p16, and PI3K, among others. Strategies to address epidermal growth factor receptor (EGFR) resistance by targeting alternative downstream signals (such as src) are the focus of ongoing trials. (See <a class="local">'Disruption of mitogenic signaling pathways'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The association of HNSCC with oncogenic human papillomavirus (HPV) is a risk factor for developing oropharyngeal cancer. HPV associated tumors have a better prognosis than do those that are not HPV associated, and treatment may evolve to account for HPV status. (See <a class="local">'Disruption of cell cycle control'</a> above and <a class="local">'Human papillomavirus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HPV associated and non-HPV associated HNSCC are among the highly immune-infiltrated cancer types with immunoregulatory influence poised to benefit from approaches that target immunoregulation with immune checkpoint inhibitors. (See <a class="local">'Immune landscape and PD-1/PD-L1 pathway in HNSCC'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our understanding of the role of immune infiltration, activation, and immunoregulatory influence in HNSCC is evolving. RNA profiling to identify "active immune class," "exhausted immune class," and "non-immune class" subgroups in HNSCC could play a role in tailoring and optimizing immunotherapeutic strategies for future clinical trials. (See <a class="local">'Immune landscape and PD-1/PD-L1 pathway in HNSCC'</a> above.)</p><p></p><p class="headingAnchor" id="H261344485"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Shanthi Marur, MD, MBBS, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61:759.</a></li><li><a class="nounderline abstract_t">Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159.</a></li><li><a class="nounderline abstract_t">Patel V, Yeudall WA, Gardner A, et al. Consistent chromosomal anomalies in keratinocyte cell lines derived from untreated malignant lesions of the oral cavity. Genes Chromosomes Cancer 1993; 7:109.</a></li><li><a class="nounderline abstract_t">Van Dyke DL, Worsham MJ, Benninger MS, et al. Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosomes Cancer 1994; 9:192.</a></li><li><a class="nounderline abstract_t">Cowan JM, Beckett MA, Ahmed-Swan S, Weichselbaum RR. Cytogenetic evidence of the multistep origin of head and neck squamous cell carcinomas. J Natl Cancer Inst 1992; 84:793.</a></li><li><a class="nounderline abstract_t">Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996; 56:2488.</a></li><li><a class="nounderline abstract_t">Ha PK, Benoit NE, Yochem R, et al. A transcriptional progression model for head and neck cancer. Clin Cancer Res 2003; 9:3058.</a></li><li><a class="nounderline abstract_t">Loyo M, Li RJ, Bettegowda C, et al. Lessons learned from next-generation sequencing in head and neck cancer. Head Neck 2013; 35:454.</a></li><li><a class="nounderline abstract_t">Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333:1154.</a></li><li><a class="nounderline abstract_t">Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333:1157.</a></li><li><a class="nounderline abstract_t">Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6:963.</a></li><li><a class="nounderline abstract_t">Partridge M, Emilion G, Pateromichelakis S, et al. Field cancerisation of the oral cavity: comparison of the spectrum of molecular alterations in cases presenting with both dysplastic and malignant lesions. Oral Oncol 1997; 33:332.</a></li><li><a class="nounderline abstract_t">Partridge M, Pateromichelakis S, Phillips E, et al. Profiling clonality and progression in multiple premalignant and malignant oral lesions identifies a subgroup of cases with a distinct presentation of squamous cell carcinoma. Clin Cancer Res 2001; 7:1860.</a></li><li><a class="nounderline abstract_t">Bosatra A, Bussani R, Silvestri F. From epithelial dysplasia to squamous carcinoma in the head and neck region: an epidemiological assessment. Acta Otolaryngol Suppl 1997; 527:47.</a></li><li><a class="nounderline abstract_t">Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992; 52:5407.</a></li><li><a class="nounderline abstract_t">Chung CH, Guthrie VB, Masica DL, et al. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol 2015; 26:1216.</a></li><li><a class="nounderline abstract_t">Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000; 6:357.</a></li><li><a class="nounderline abstract_t">Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996; 2:682.</a></li><li><a class="nounderline abstract_t">Carvalho AL, Chuang A, Jiang WW, et al. Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res 2006; 66:9401.</a></li><li><a class="nounderline abstract_t">Chang KP, Wang CI, Pickering CR, et al. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma. Head Neck 2017; 39:1131.</a></li><li><a class="nounderline abstract_t">Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001; 345:1890.</a></li><li><a class="nounderline abstract_t">van der Riet P, Nawroz H, Hruban RH, et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 1994; 54:1156.</a></li><li><a class="nounderline abstract_t">Bockmühl U, Wolf G, Schmidt S, et al. Genomic alterations associated with malignancy in head and neck cancer. Head Neck 1998; 20:145.</a></li><li><a class="nounderline abstract_t">Mithani SK, Mydlarz WK, Grumbine FL, et al. Molecular genetics of premalignant oral lesions. Oral Dis 2007; 13:126.</a></li><li><a class="nounderline abstract_t">Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525.</a></li><li><a class="nounderline abstract_t">Wreesmann VB, Shi W, Thaler HT, et al. Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck. J Clin Oncol 2004; 22:3965.</a></li><li><a class="nounderline abstract_t">Bérgamo NA, da Silva Veiga LC, dos Reis PP, et al. Classic and molecular cytogenetic analyses reveal chromosomal gains and losses correlated with survival in head and neck cancer patients. Clin Cancer Res 2005; 11:621.</a></li><li><a class="nounderline abstract_t">Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517:576.</a></li><li><a class="nounderline abstract_t">Morris LGT, Chandramohan R, West L, et al. The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform. JAMA Oncol 2017; 3:244.</a></li><li><a class="nounderline abstract_t">Chau NG, Li YY, Jo VY, et al. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 2016; 22:2939.</a></li><li><a class="nounderline abstract_t">Kiaris H, Spandidos DA, Jones AS, et al. Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. Br J Cancer 1995; 72:123.</a></li><li><a class="nounderline abstract_t">Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54:3153.</a></li><li><a class="nounderline abstract_t">Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53:3579.</a></li><li><a class="nounderline abstract_t">Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25:2164.</a></li><li><a class="nounderline abstract_t">Eisbruch A, Blick M, Lee JS, et al. Analysis of the epidermal growth factor receptor gene in fresh human head and neck tumors. Cancer Res 1987; 47:3603.</a></li><li><a class="nounderline abstract_t">Rubin Grandis J, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 1998; 4:13.</a></li><li><a class="nounderline abstract_t">Craven JM, Pavelic ZP, Stambrook PJ, et al. Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res 1992; 12:2273.</a></li><li><a class="nounderline abstract_t">Field JK, Spandidos DA, Yiagnisis M, et al. C-erbB-2 expression in squamous cell carcinoma of the head and neck. Anticancer Res 1992; 12:613.</a></li><li><a class="nounderline abstract_t">Xia W, Lau YK, Zhang HZ, et al. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res 1997; 3:3.</a></li><li><a class="nounderline abstract_t">Zhu X, Zhang F, Zhang W, et al. Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis. J Surg Oncol 2013; 108:387.</a></li><li><a class="nounderline abstract_t">Pomerantz RG, Grandis JR. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol 2004; 31:734.</a></li><li><a class="nounderline abstract_t">Sathyan KM, Nalinakumari KR, Kannan S. H-Ras mutation modulates the expression of major cell cycle regulatory proteins and disease prognosis in oral carcinoma. Mod Pathol 2007; 20:1141.</a></li><li><a class="nounderline abstract_t">Saranath D, Chang SE, Bhoite LT, et al. High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer 1991; 63:573.</a></li><li><a class="nounderline abstract_t">Qiu W, Schönleben F, Li X, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12:1441.</a></li><li><a class="nounderline abstract_t">Murugan AK, Hong NT, Fukui Y, et al. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol 2008; 32:101.</a></li><li><a class="nounderline abstract_t">Xia W, Lau YK, Zhang HZ, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999; 5:4164.</a></li><li><a class="nounderline abstract_t">Chen IH, Chang JT, Liao CT, et al. Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis. Br J Cancer 2003; 89:681.</a></li><li><a class="nounderline abstract_t">Giatromanolaki A, Koukourakis MI, Sivridis E, Fountzilas G. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival. Anticancer Res 2000; 20:997.</a></li><li><a class="nounderline abstract_t">Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004; 4:470.</a></li><li><a class="nounderline abstract_t">Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 2006; 6:231.</a></li><li><a class="nounderline abstract_t">Zhang Q, Thomas SM, Xi S, et al. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004; 64:6166.</a></li><li><a class="nounderline abstract_t">Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531.</a></li><li><a class="nounderline abstract_t">Lang L, Shay C, Xiong Y, et al. Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib. J Hematol Oncol 2018; 11:85.</a></li><li><a class="nounderline abstract_t">Kotelnikov VM, Coon JS 4th, Mundle S, et al. Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis. Clin Cancer Res 1997; 3:95.</a></li><li><a class="nounderline abstract_t">Akervall JA, Michalides RJ, Mineta H, et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 1997; 79:380.</a></li><li><a class="nounderline abstract_t">Holley SL, Matthias C, Jahnke V, et al. Association of cyclin D1 polymorphism with increased susceptibility to oral squamous cell carcinoma. Oral Oncol 2005; 41:156.</a></li><li><a class="nounderline abstract_t">Matthias C, Harréus U, Strange R. Influential factors on tumor recurrence in head and neck cancer patients. Eur Arch Otorhinolaryngol 2006; 263:37.</a></li><li><a class="nounderline abstract_t">Michalides R, van Veelen N, Hart A, et al. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995; 55:975.</a></li><li><a class="nounderline abstract_t">Marsit CJ, Black CC, Posner MR, Kelsey KT. A genotype-phenotype examination of cyclin D1 on risk and outcome of squamous cell carcinoma of the head and neck. Clin Cancer Res 2008; 14:2371.</a></li><li><a class="nounderline abstract_t">Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996; 56:3630.</a></li><li><a class="nounderline abstract_t">Liggett WH Jr, Sewell DA, Rocco J, et al. p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res 1996; 56:4119.</a></li><li><a class="nounderline abstract_t">Rocco JW, Li D, Liggett WH Jr, et al. p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res 1998; 4:1697.</a></li><li><a class="nounderline abstract_t">Shin DM, Kim J, Ro JY, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54:321.</a></li><li><a class="nounderline abstract_t">Chung KY, Mukhopadhyay T, Kim J, et al. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res 1993; 53:1676.</a></li><li><a class="nounderline abstract_t">Boyle JO, Hakim J, Koch W, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993; 53:4477.</a></li><li><a class="nounderline abstract_t">Gasco M, Crook T. The p53 network in head and neck cancer. Oral Oncol 2003; 39:222.</a></li><li><a class="nounderline abstract_t">Olshan AF, Weissler MC, Pei H, Conway K. p53 mutations in head and neck cancer: new data and evaluation of mutational spectra. Cancer Epidemiol Biomarkers Prev 1997; 6:499.</a></li><li><a class="nounderline abstract_t">González MV, Pello MF, López-Larrea C, et al. Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck. Clin Cancer Res 1995; 1:1043.</a></li><li><a class="nounderline abstract_t">Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63:1129.</a></li><li><a class="nounderline abstract_t">Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007; 357:2552.</a></li><li><a class="nounderline abstract_t">Balz V, Scheckenbach K, Götte K, et al. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003; 63:1188.</a></li><li><a class="nounderline abstract_t">Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995; 332:712.</a></li><li><a class="nounderline abstract_t">Field JK, Zoumpourlis V, Spandidos DA, Jones AS. p53 expression and mutations in squamous cell carcinoma of the head and neck: expression correlates with the patients' use of tobacco and alcohol. Cancer Detect Prev 1994; 18:197.</a></li><li><a class="nounderline abstract_t">Koch WM, Brennan JA, Zahurak M, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88:1580.</a></li><li><a class="nounderline abstract_t">Mineta H, Borg A, Dictor M, et al. p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer 1998; 78:1084.</a></li><li><a class="nounderline abstract_t">Geisler SA, Olshan AF, Weissler MC, et al. p16 and p53 Protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 2002; 8:3445.</a></li><li><a class="nounderline abstract_t">Temam S, Flahault A, Périé S, et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2000; 18:385.</a></li><li><a class="nounderline abstract_t">Osman I, Sherman E, Singh B, et al. Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. J Clin Oncol 2002; 20:2980.</a></li><li><a class="nounderline abstract_t">Kimple RJ, Smith MA, Blitzer GC, et al. Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res 2013; 73:4791.</a></li><li><a class="nounderline abstract_t">Field JK, Spandidos DA, Stell PM, et al. Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 1989; 4:1463.</a></li><li><a class="nounderline abstract_t">Zhao X, Shu D, Sun W, et al. PLEK2 promotes cancer stemness and tumorigenesis of head and neck squamous cell carcinoma via the c-Myc-mediated positive feedback loop. Cancer Commun (Lond) 2022; 42:987.</a></li><li><a class="nounderline abstract_t">Arantes LMRB, Cruvinel-Carloni A, de Carvalho AC, et al. TERT Promoter Mutation C228T Increases Risk for Tumor Recurrence and Death in Head and Neck Cancer Patients. Front Oncol 2020; 10:1275.</a></li><li><a class="nounderline abstract_t">Xu XC, Ro JY, Lee JS, et al. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res 1994; 54:3580.</a></li><li><a class="nounderline abstract_t">Khuri FR, Lippman SM, Spitz MR, et al. Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst 1997; 89:199.</a></li><li><a class="nounderline abstract_t">Papadimitrakopoulou VA, Hong WK. Retinoids in head and neck chemoprevention. Proc Soc Exp Biol Med 1997; 216:283.</a></li><li><a class="nounderline abstract_t">Frixen UH, Behrens J, Sachs M, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113:173.</a></li><li><a class="nounderline abstract_t">Schipper JH, Frixen UH, Behrens J, et al. E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res 1991; 51:6328.</a></li><li><a class="nounderline abstract_t">Lim SC, Zhang S, Ishii G, et al. Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue. Clin Cancer Res 2004; 10:166.</a></li><li><a class="nounderline abstract_t">López-Verdín S, Martínez-Fierro ML, Garza-Veloz I, et al. E-Cadherin gene expression in oral cancer: Clinical and prospective data. Med Oral Patol Oral Cir Bucal 2019; 24:e444.</a></li><li><a class="nounderline abstract_t">Johansson N, Airola K, Grénman R, et al. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997; 151:499.</a></li><li><a class="nounderline abstract_t">de Vicente JC, Lequerica-Fernández P, López-Arranz JS, et al. Expression of matrix metalloproteinase-9 in high-grade salivary gland carcinomas is associated with their metastatic potential. Laryngoscope 2008; 118:247.</a></li><li><a class="nounderline abstract_t">O-Charoenrat P, Rhys-Evans P, Modjtahedi H, et al. Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion. Int J Cancer 2000; 86:307.</a></li><li><a class="nounderline abstract_t">Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein. Clin Cancer Res 2005; 11:3257.</a></li><li><a class="nounderline abstract_t">Katayama A, Bandoh N, Kishibe K, et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 2004; 10:634.</a></li><li><a class="nounderline abstract_t">Nayak CS, Carvalho AL, Jeronimo C, et al. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma. Laryngoscope 2007; 117:1376.</a></li><li><a class="nounderline abstract_t">Vihinen P, Ala-aho R, Kähäri VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005; 5:203.</a></li><li class="breakAll">Rudin CM, Thompson CB. Apoptosis and cancer. In: The Genetic Basis of Human Cancer, Vogelstein B, Kinzler KW (Eds), McGraw-Hill, New York 1997. p.193.</li><li><a class="nounderline abstract_t">Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69:119.</a></li><li><a class="nounderline abstract_t">White E. Life, death, and the pursuit of apoptosis. Genes Dev 1996; 10:1.</a></li><li><a class="nounderline abstract_t">Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997; 3:614.</a></li><li><a class="nounderline abstract_t">Pena JC, Thompson CB, Recant W, et al. Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer 1999; 85:164.</a></li><li><a class="nounderline abstract_t">Wilson GD, Grover R, Richman PI, et al. Bcl-2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy. Anticancer Res 1996; 16:2403.</a></li><li><a class="nounderline abstract_t">Trask DK, Wolf GT, Bradford CR, et al. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope 2002; 112:638.</a></li><li><a class="nounderline abstract_t">Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013; 73:1733.</a></li><li><a class="nounderline abstract_t">Qiao XW, Jiang J, Pang X, et al. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer. Front Immunol 2020; 11:1721.</a></li><li><a class="nounderline abstract_t">Tsushima F, Tanaka K, Otsuki N, et al. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol 2006; 42:268.</a></li><li><a class="nounderline abstract_t">Chen J, Feng Y, Lu L, et al. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 2012; 217:385.</a></li><li><a class="nounderline abstract_t">Huang SK, Ezri MD, Hauser RG, Denes P. Carotid sinus hypersensitivity in patients with unexplained syncope: clinical, electrophysiologic, and long-term follow-up observations. Am Heart J 1988; 116:989.</a></li><li><a class="nounderline abstract_t">Lin YM, Sung WW, Hsieh MJ, et al. High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. PLoS One 2015; 10:e0142656.</a></li><li><a class="nounderline abstract_t">Moratin J, Metzger K, Safaltin A, et al. Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma. Head Neck 2019; 41:2484.</a></li><li><a class="nounderline abstract_t">Balermpas P, Rödel F, Krause M, et al. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer 2017; 141:594.</a></li><li><a class="nounderline abstract_t">Yang WF, Wong MCM, Thomson PJ, et al. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncol 2018; 86:81.</a></li><li><a class="nounderline abstract_t">Kim HR, Ha SJ, Hong MH, et al. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Sci Rep 2016; 6:36956.</a></li><li><a class="nounderline abstract_t">Mandal R, Şenbabaoğlu Y, Desrichard A, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016; 1:e89829.</a></li><li><a class="nounderline abstract_t">Marur S, Li S, Cmelak AJ, et al. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol 2016; :JCO2016683300.</a></li><li><a class="nounderline abstract_t">O'Sullivan B, Huang SH, Su J, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 2016; 17:440.</a></li><li><a class="nounderline abstract_t">Gillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 2012; 30:2102.</a></li><li><a class="nounderline abstract_t">Chen YP, Wang YQ, Lv JW, et al. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. Ann Oncol 2019; 30:68.</a></li></ol></div><div id="topicVersionRevision">Topic 3387 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2188735" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A genetic model for colorectal tumorigenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8861899" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Lessons from hereditary colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7687452" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Consistent chromosomal anomalies in keratinocyte cell lines derived from untreated malignant lesions of the oral cavity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7515662" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1573667" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cytogenetic evidence of the multistep origin of head and neck squamous cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8653682" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Genetic progression model for head and neck cancer: implications for field cancerization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12912957" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A transcriptional progression model for head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22907887" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lessons learned from next-generation sequencing in head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21798897" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21798893" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The mutational landscape of head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13094644" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9415332" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Field cancerisation of the oral cavity: comparison of the spectrum of molecular alterations in cases presenting with both dysplastic and malignant lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11448897" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Profiling clonality and progression in multiple premalignant and malignant oral lesions identifies a subgroup of cases with a distinct presentation of squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9197480" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : From epithelial dysplasia to squamous carcinoma in the head and neck region: an epidemiological assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1394146" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25712460" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10690511" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8640560" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17018594" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28230921" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11756581" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8118798" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Frequent loss of chromosome 9p21-22 early in head and neck cancer progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9484946" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Genomic alterations associated with malignancy in head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17305612" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Molecular genetics of premalignant oral lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2841597" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Genetic alterations during colorectal-tumor development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15459219" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15701849" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Classic and molecular cytogenetic analyses reveal chromosomal gains and losses correlated with survival in head and neck cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25631445" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comprehensive genomic characterization of head and neck squamous cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27442865" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26763254" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7599040" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8205534" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8339264" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17538160" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3581091" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Analysis of the epidermal growth factor receptor gene in fresh human head and neck tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9516947" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1363518" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Expression of c-erbB-2 gene in human head and neck carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1377893" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : C-erbB-2 expression in squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815530" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24038070" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15599851" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17767136" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : H-Ras mutation modulates the expression of major cell cycle regulatory proteins and disease prognosis in oral carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2021541" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16533766" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : PIK3CA mutations in head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18097548" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10632356" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915878" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prognostic significance of EGFR and Her-2 in oral cavity cancer in betel quid prevalent area cancer prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10810387" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15170449" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A renaissance for SRC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16503733" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : STAT3 as a therapeutic target in head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15342401" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16775234" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29925404" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815543" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9010112" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15695117" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Association of cyclin D1 polymorphism with increased susceptibility to oral squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16003553" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Influential factors on tumor recurrence in head and neck cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7867006" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18413827" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A genotype-phenotype examination of cyclin D1 on risk and outcome of squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8705996" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8797577" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9676844" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8275461" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8453641" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8402617" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The incidence of p53 mutations increases with progression of head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12618194" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The p53 network in head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9232336" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : p53 mutations in head and neck cancer: new data and evaluation of mutational spectra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9816078" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2175676" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094376" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : TP53 mutations and survival in squamous-cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12649174" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7854378" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8076382" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : p53 expression and mutations in squamous cell carcinoma of the head and neck: expression correlates with the patients' use of tobacco and alcohol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8901856" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9792155" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12429633" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : p16 and p53 Protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10637254" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12089228" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23749640" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Enhanced radiation sensitivity in HPV-positive head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2687767" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36002342" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : PLEK2 promotes cancer stemness and tumorigenesis of head and neck squamous cell carcinoma via the c-Myc-mediated positive feedback loop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32850388" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : TERT Promoter Mutation C228T Increases Risk for Tumor Recurrence and Death in Head and Neck Cancer Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8012985" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9017000" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Molecular epidemiology and retinoid chemoprevention of head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9349698" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Retinoids in head and neck chemoprevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2007622" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1933895" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14734465" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31256188" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : E-Cadherin gene expression in oral cancer: Clinical and prospective data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9250162" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18000467" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Expression of matrix metalloproteinase-9 in high-grade salivary gland carcinomas is associated with their metastatic potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10760816" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15867221" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14760086" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17592394" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15892620" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Matrix metalloproteinases as therapeutic targets in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15892620" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Matrix metalloproteinases as therapeutic targets in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1555236" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Induction of apoptosis in fibroblasts by c-myc protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8557188" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Life, death, and the pursuit of apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9176486" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The proto-oncogene Bcl-2 and its role in regulating apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9921989" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8816842" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Bcl-2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12150516" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23288508" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33072064" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16271509" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22204817" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3177198" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Carotid sinus hypersensitivity in patients with unexplained syncope: clinical, electrophysiologic, and long-term follow-up observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26562534" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30821864" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28480996" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30409325" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27841362" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27777979" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : The head and neck cancer immune landscape and its immunotherapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28029303" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26936027" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22565003" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30407504" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
